Filtered By:
Source: JAHA:Journal of the American Heart Association
Condition: Ischemic Stroke
Drug: Plavix
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack Stroke
Conclusions Among patients treated within 12 hours, the combination of clopidogrel and aspirin was more effective than aspirin alone in reducing the risk of recurrent ischemic stroke during the 90-day follow-up and did not increase the hemorrhagic risk. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00979589.
Source: JAHA:Journal of the American Heart Association - March 20, 2016 Category: Cardiology Authors: Li, Z., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., Meng, X., Li, H., Pan, Y., Wang, X., Wang, C., Yang, X., Zhang, C., Jing, J., Xian, Y., Johnston, S. C., Wang, Y., on behalf of the CHANCE Investigators Tags: Secondary Prevention, Ischemic Stroke, Transient Ischemic Attack (TIA) Source Type: research

Cost-Effectiveness of Clopidogrel-Aspirin Versus Aspirin Alone for Acute Transient Ischemic Attack and Minor Stroke Stroke
Conclusions Early 90-day clopidogrel-aspirin regimen for acute TIA or minor stroke is highly cost-effective in China. Although clopidogrel is generic, Plavix is brand in China. If Plavix were generic, treatment with clopidogrel-aspirin would have been cost saving.
Source: JAHA:Journal of the American Heart Association - June 5, 2014 Category: Cardiology Authors: Pan, Y., Wang, A., Liu, G., Zhao, X., Meng, X., Zhao, K., Liu, L., Wang, C., Johnston, S. C., Wang, Y., Wang, Y., the CHANCE Investigators Tags: Stroke Source Type: research

Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials Coronary Heart Disease
Conclusions In CREDO, the efficacy of clopidogrel was not significantly affected by PPI use. However, in CAPRIE, clopidogrel was beneficial to non-PPI users while apparently harmful to PPI users. Whether this negative interaction is clinically important for patients receiving clopidogrel without aspirin needs further study.
Source: JAHA:Journal of the American Heart Association - January 15, 2013 Category: Cardiology Authors: Dunn, S. P., Steinhubl, S. R., Bauer, D., Charnigo, R. J., Berger, P. B., Topol, E. J. Tags: Coronary Heart Disease Source Type: research

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study Coronary Heart Disease
Conclusions In community practice, prasugrel use may be driven more by bleeding risk rather than ischemic benefit. This may result in underutilization of higher potency ADP receptor inhibitor among patients more likely to derive ischemic benefit.
Source: JAHA:Journal of the American Heart Association - September 22, 2016 Category: Cardiology Authors: Vora, A. N., Peterson, E. D., McCoy, L. A., Effron, M. B., Anstrom, K. J., Faries, D. E., Zettler, M. E., Fonarow, G. C., Baker, B. A., Stone, G. W., Wang, T. Y. Tags: Acute Coronary Syndromes, Coronary Artery Disease Coronary Heart Disease Source Type: research